Patient-Specific Risk Assessment
The ArteraAI Prostate Test (mHSPC) is the first AI-powered test that provides individualized 5-year PCSM risk estimates for patients with metastatic hormone-sensitive prostate cancer. Results help guide therapy intensity and duration decisions, balancing efficacy and quality of life considerations.
Fast and convenient
Since the test uses digitized images from the patient's diagnostic prostate biopsy slides and clinical information, test results can be shared within 1-2 days after specimen receipt. There's no tissue consumption or risk of insufficient tissue sample leading to inconclusive results.
Rigorous Validation
The ArteraAI Prostate Test (mHSPC) was validated in 1,598 patients with metastatic prostate cancer from the STAMPEDE phase III trial. The underlying multimodal artificial intelligence (MMAI) platform has been validated in thousands of patients across multiple clinical trials.
Developed to Guide Treatment Decisions in mHSPC
Medical oncologists treating mHSPC patients face a critical decision: should patients receive doublet therapy (ADT + ARPI) or escalate to triplet therapy with docetaxel? Traditional risk factors like metastatic volume provide broad categories but lack the precision needed to confidently personalize treatment.
The ArteraAI Prostate Test provides a patient-specific 5-year PCSM risk estimate based on doublet hormone therapy (ADT + ARPI). This individualized assessment refines risk stratification beyond volume alone, helping clinicians balance treatment efficacy against the known toxicities of therapy intensification.
Risk Stratification Within Metastatic Volume Subgroups
Two Ways to Order the ArteraAI Prostate Test (mHSPC)
Order Directly Through Artera (Available Now)
Our team will guide you through account activation and provide all necessary forms and support.
Order Through Tempus (Available Soon)
For physicians who use Tempus for comprehensive genomic profiling, you will soon be able to add the ArteraAI Prostate Test (mHSPC) to your Tempus xT CDx, xT, or xR orders. Sign up to be notified when this option becomes available.
Test Guide
This brochure provides an explanation of how the ArteraAI Prostate Test (mHSPC) works, how it was validated, and how it can be used to inform treatment planning for patients with metastatic hormone-sensitive prostate cancer.
Test Requisition Form
The test requisition form can be completed and faxed into Artera to order the ArteraAI Prostate Test for a patient. This form requires an ordering clinician signature.
Sample Test Report
This is a sample test report to show how the ArteraAI Prostate Test (mHSPC) results will appear when testing is completed.
Ordering is Easy with Artera
The ArteraAI Prostate Test is a laboratory-developed testTesting is performed by ArteraAI, located at 6800 Southpoint Pkwy Suite 950, Jacksonville, Florida 32216. The ArteraAI Prostate Test was developed and its performance characteristics were determined by ArteraAI. This Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) as qualified to perform high-complexity clinical laboratory testing. This test is used for clinical purposes and should not be regarded as investigational or for research. This test has not been cleared or approved by the U.S. Food and Drug Administration. that is now clinically available through a single CLIA-certified laboratory in Jacksonville, FL.
Yes! You can visit the ArteraAI Prostate Test report page to explore each section of the report to better understand the results.
The ArteraAI Prostate Test (mHSPC) is intended to assist clinicians with risk-based decisions for patients with metastatic hormone-sensitive prostate cancer within recommended clinical treatment guidelines.
The out-of-pocket cost for the ArteraAI Prostate Test will be based on the patient’s insurance plan. If the patient is covered by Medicare Plan B, they should have zero out-of-pocket costs for the ArteraAI Prostate Test. If the patient is covered by private insurance, financial liability will be subject to the terms of their plan taking into consideration copays, coinsurance and deductibles. Patients should contact billing@artera.ai for additional questions about their estimated out-of-pocket liability for the test.
The ArteraAI Prostate Test can be ordered in all 50 US states. We also have partners in Puerto Rico, United Kingdom, Australia, and Israel where versions of the ArteraAI Prostate Test are available through our partnerships. Please reach out to support@artera.ai for additional details or if you are located outside the listed geographies and are interested in placing an order.
After you reach out to us, a member of our Sales team will set up an account in the Artera Portal to enable order submission. You and/or an ordering delegate will receive login instructions and once an order is placed, the Customer Success Team will contact the pathology lab to arrange all necessary logistics to ship the histopathology sample to our CLIA-certified laboratory in Florida.
Alternatively, you can fill out and fax in a Test Requisition Form to place an order as well.
No. Ordering of the ArteraAI Prostate Test is limited to clinicians whose license and scope of practice allows them to order the test. However, we encourage patients to share information about ArteraAI with their doctor.
The ArteraAI Prostate Test results are typically ready within 1-2 days after receipt of the patient’s specimen in our CLIA-certified lab. The clinician can access the patient’s report via an online portal or have it faxed.
Order the ArteraAI Prostate Test for your patient. Start your order
